Back to Top Skip to main content
Need larger text?

2015 Meetings

In the event the class of drugs specified herein has previously been reviewed, the government solicits quotes for new Blanket Purchase Agreements (BPAs)/Voluntary Agreement for Retail Refunds (VARRs) to replace any existing BPAs/VARRs. The government will not consider existing BPA/VARR prices in the Uniform Formulary (UF) evaluation. Any existing BPA/VARR for this class of drugs will be terminated upon the conclusion of the UF decision.

Meeting Date  Review Type  Drug Classes/New Drugs Under Review/Information for Manufacturers  Meeting Window for Manufacturers to give Clinical/Cost Presentation 

February 2015

 Class Review Oral Oncological Agents/Prostate I & II

December 2014

Belsomra - Solicitation Cancelled

 

 
Class Review Transmucosal Immediate Rlease Fentanyl
Class Review Pulmonary Aterial Hypertension Agents
Designated Newly Approved Drugs  Zonitivity, Hetlioz, Belsomra, Jardiance, Esomeprasole Strontium, Stendra 

May 2015

 Class Review Newer Oral Anticoagulants and Warfarin March 2015
Class Review  Hepatitis Antivirals (Hepatitis C)
Designated Newly Approved Drugs Belsomra, Plegridy, Diclegis
August 2015 Class Review Diabetes Non-Insulin (GLP-1 Receptor Agonists) June 2015
Class Review  Diabetes Non-Insulin (SGLT-2 Inhibitors)
Class Review Narcotic Analgesics - Long Acting
Class Review Oncological Agents - CML Drugs
Designated Newly Approved Drugs  Incruse Ellipta, Cosentyx
November 2015 Class Review Attention Deficit Hyperactivity Disorder - Stimulants

October 2015
Class Review  Antirheumatics - Injectable Methorexate 
Class Review  Gastrointestinal-2 Agents - Miscellaneous
Class Reveiw  Acne - Isotretinoids 
Designated Newly Approved Drugs  Namenda XR, Namzaric

Subject to Change Disclaimer

The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.

If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing: Download a PDF Reader or learn more about PDFs.
You are leaving Health.mil

The appearance of hyperlinks does not constitute endorsement by the Defense Health Agency of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.

 You are leaving Health.mil View the external links disclaimer. OK Cancel